Exco InTouch announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology guidelines for Health Insurance Portability and Accountability Act security.
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology (NIST) guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.
HIPAA rules constitute a set of regulations from the US Department of Health & Human Services relating to any Protected Health Information (PHI) that identifies health or financial data of US citizens stored on computer systems. The Security Rule specifies a series of administrative, physical, and technical safeguards for covered entities and their business associates to use to assure the confidentiality, integrity, and availability of electronic PHI.
Dale Jessop, Chief Technology Officer at Exco InTouch commented “Security of data and the protection of personal information remain the highest priority for Exco InTouch. Whilst no formal certification for HIPAA exists, to be independently audited against NIST guidelines for HIPAA security provides further reassurance to our customers that Exco InTouch business operations are aligned to comply with HIPAA standards.”
Tim Davis, CEO and co-founder of Exco InTouch added “I am extremely proud of the team involved throughout the audit process, and also that of the 64 HIPAA citations we were audited on, no findings were reported". As a result of this audit, Exco InTouch customers (for whom the company provides mobile and digital patient engagement solutions), can continue to be assured that their programs comply with these stringent security safeguards.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.